EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls

While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations centered mostly on improving existing approaches. Which areas of multiple sclerosis treatment need more options?

At the end of March, the EMA made key decisions on three treatments for multiple sclerosis (MS), a chronic neurodegenerative disease affecting 2.5 million people worldwide

The regulator greenlit Kesimpta, a drug developed by Novartis and licensed from the Danish biotech Genmab. The EMA also gave the nod to a subcutaneous version of an approved intravenous drug from Biogen called Tysabri. Finally, the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended the approval of Ponvory, a drug developed by Johnson & Johnson and approved by the FDA in mid-March.

While the announcements seemed to coincide neatly, this was most likely due to chance, said Jon Moore, CEO of the UK biotech Pheno Therapeutics and Operating Partner at Advent Life Sciences. “These things can come along in threes just like buses sometimes do.”


The post EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls appeared first on Labiotech.eu.

Published on Tue, 27 Apr 2021 10:20:40 +0000 on behalf of salesforce collection starts with string